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Cytoadherence of Plasmodium-falciparum-parasitized red blood cells (PRBCs) to host receptors is the key phenomenon in the
pathological process of the malaria disease. Some of these interactions can originate poor outcomes responsible for 1 to 3 mil-
lion annual deaths mostly occurring among children in sub-Saharan Africa. Pregnancy-associated malaria (PAM) represents an
important exception of the disease occurring at adulthood in malaria endemic settings. Consequences of this are shared between
the mother (maternal anemia) and the baby (low birth weight and infant mortality). Demonstrating that parasites causing PAM
expressspeciﬁcvariantsurfaceantigens(VSAPAM),includingtheP.falciparumerythrocytemembraneprotein1(PfEMP1)variant
VAR2CSA, that are targets for protective immunity has strengthened the possibility for the development of PAM-speciﬁc vaccine.
In this paper, we review the molecular basis of malaria pathogenesis attributable to the erythrocyte stages of the parasites, and
ﬁndings supporting potential anti-PAM vaccine components evidenced in PAM.
Copyright © 2007 N. T. Ndam and P. Deloron. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. THE IMPORTANCE OF CYTOADHERENCE IN
THE PATHOPHYSIOLOGY OF PLASMODIUM
FALCIPARUM MALARIA
P. falciparum infection encompasses a full range of clinical
presentations, from asymptomatic infection to severe dis-
ease, including cerebral malaria, severe anemia, acute res-
piratory failure, hypoglycemia, renal failure, and pulmonary
edema. Severe malaria, in particular cerebral malaria and se-
vere anemia, constitutes one of the main causes of hospital-
ization in nonimmune individual from malaria endemic ar-
eas [1]. Patients with cerebral malaria present with a loss of
consciousness and a coma, related to vascular obstruction by
aggregated parasitized red blood cells (PRBCs), rosettes, and
otherﬁbrillouscomponents.Parasitefactors,suchasGPIan-
chors elements (glycosylphosphatidylinositol), induce TNF-
α and INF-γ, production that in turn will induce overex-
pression and relocalization of endothelial receptors, such as
ICAM-1 and PECAM-1. In severe anemia, human and para-
site factors play major roles. Anemia for instance is the con-
sequence of PRBCs destruction, insuﬃcient erythrocyte pro-
duction, and increased clearance of both infected and non-
infected RBCs by the spleen and the macrophages [2–5].
To survive, most microorganisms proceed to evolution-
ary adjustments in their virulence factors. In Plasmodium
spp, these changes allow the parasite to sustain a chronicity
inside its host by means of constant antigenic variations, al-
lowing its transmission to the mosquito. Two virulence fac-
tors have been described in P. falciparum. Firstly, the grow-
ing rate, as parasites isolated from patients presenting with
severe malaria express an in vitro multiplication rate higher
than that of parasites isolated from nonsevere malaria pa-
tients [2].
This suggests that parasites causing severe disease multi-
ply in their host faster than parasites associated with non-
severe disease. Factors controlling parasite multiplication
rate still are not identiﬁed. The other P. falciparum vir-
ulence factor is the cytoadherence phenomenon (for re-
view, see [6–8]). The nature of the PfEMP1 protein ex-
pressed on the surface of PRBCs plays a key role in this
process. Parasites unable to adhere to vascular endothelium
are eliminated from the blood stream by the spleen ﬁl-
ter. Indeed, erythrocytes do lose their deformability when
parasitized, facilitating their clearance by the spleen. (for
review, see [9]). RBCs surface expression of variant anti-
gens constitutes an evasion strategy from the immune sys-
tem, used by all Plasmodium species studied, and this may2 Journal of Biomedicine and Biotechnology
probably represent a common feature within the Plasmod-
ium genus. The expression of antigens unknown from the
MHC would represent an excellent way to escape the im-
mune system, but would also constitute a threat for species
survival. The alternate expression of RBCs surface antigens
thus is one of the intrahost mechanisms used by parasites
for controlling their own population, while avoiding their
host’s death related to an excessive parasite multiplication
[10, 11].
In P. falciparum, at least two variable surface antigens
(VSAs), PfEMP1 and RIFINs, are expressed on the surface
of PRBCs [12]. Although members of the STEVORs family
have been identiﬁed in Maurer’s dots, a network of parasite
microtubules inside the cytoplasm of PRBCs, these proteins
may not be surface-exposed [13, 14]. All these three proteins
are encoded by multigene families, and most of the genes
composing each family are in a sub-telomeric location, an
areasubjectedtoahighlevelofrecombination.Variationsaf-
fecting VSAs suggest that they are necessary for the parasite
survival. Despite the changes needed for immune evasion,
the limited number of host receptors imposes the parasite to
maintain a minimum stability between structure and func-
tion of its surface proteins by maintaining selected amino
acids residues.
2. PARASITIZED RED BLOOD CELLS ADHERENCE
AdherenceofPRBCstoendothelialreceptorsisacharacteris-
tic of P. falciparum infections [15]. While PRBCs containing
young stages (ring) of the parasite do circulate in the blood
ﬂow without concern, those RBCs infected by mature stages
(trophozoites and schizonts) of the parasite are sequestered
in the microvasculature of deep organs [16], thus avoiding
passage through the spleen. Parasite-encoded adhesines in-
volved in the RBCs cytoadherence have been associated to
protrusions (knobs) at the surface of erythrocytes (Figure 1).
Even though adherence under physiological conditions may
require knobs, it is now admitted that these knobs are not
essential, as knobless parasite lines have been observed in
vitro to bind endothelial cells [17, 18]. However Knobs are
the location where most parasite ligands are expressed [19].
Following the demonstration of the major role the PfEMP1
protein plays in the mechanisms of PBRCs binding to en-
dothelial cells in 1984 [20], distinct adhesive properties of
these parasite proteins to various receptors were also re-
ported. The variations in the PfEMP1 binding properties
originate diﬀerent types of interactions, such as deep or-
gans tropism of PRBCs, agglutination with uninfected RBCs
(rosetting) [21] or with other PRBCs (auto-agglutination)
[22]. These various facets of PRBCs cytoadherence are in
close relation with malaria pathophysiology. The withdrawal
of mature forms from the blood ﬂow, and their accumula-
tion in deep organ microvessels may represent a pathologic
event more or less well tolerated, according to the target or-
ganand thelevelof PRBCsaccumulation.Sequestrationmay
be the key factor involved in vital organs failure, in particular
during cerebral malaria.
3. PREGNANCY-ASSOCIATED MALARIA
In areas endemic for malaria, the pregnant woman is at high
risk for malaria. Every year, twenty-ﬁve millions of preg-
nant women are exposed to malaria in sub-Saharan Africa,
and pregnancy-associated malaria (PAM) is of serious public
health concern [23]. In areas where malaria transmission is
intense, its main consequences are a low birth weight (LBW)
for the baby and a severe anemia for the mother. During
pregnancy, massive sequestration of P. falciparum parasites
in the placenta is likely to reduce maternofetal exchanges,
explaining the frequency of LBW babies born from infected
mothers. However, two recent studies have shown that preg-
nant women infected with Plasmodium vivax were also likely
to give birth to LBW babies, suggesting that local or systemic
production of selected inﬂammatory cytokines may also play
a role in the pathological process [24, 25].
Recent data show that P. falciparum parasites infecting
pregnant women express an antigenic proﬁle diﬀerent from
that of parasites involved in cerebral malaria, and more gen-
erally,fromparasitesencounteredinnonpregnanthosts[26].
This characteristic of PAM parasites is related to placenta-
expressed receptors that participate in the selection of par-
asite phenotypes with a given speciﬁcity for these receptors.
Chondroitin-sulfate A (CSA) is the major receptor for pla-
centa sequestration [27, 28], and the number of parasite
ligands involved in placenta sequestration is consequently
highly restricted as compared to those implicated in cerebral
malaria where several endothelial receptors may be involved.
Although PAM parasites do preferentially bind to CSA, vari-
able abilities were described among diﬀerent placental iso-
lates [29, 30]. Distinct subpopulations composed of strong
a n dw e a kb i n d e r sh a v eb e e no b s e rv e di nF C R 3 CSA (a sub-line
of FCR3 selected for its adhesion to CSA) using a model of
adhesion under ﬂow conditions [31]. Demonstration of dif-
ferent binding abilities among placental isolates showed par-
ticular interest as high binders were associated with high risk
of LBW [30], and transcribed higher level of var2csa com-
pared to low binders [32], emphasizing the role of var2csa in
PAM.
4. CHONDROITIN-4-SULFATE (CSA) AND PLACENTAL
RECEPTORS FOR SEQUESTRATION
Although glycosaminoglycans (GAG) have previously been
shown to be involved in sporozoite adhesion to hepatocytes
by binding to heparin-like motifs of the heparan sulfate (HS)
[33], CSA is the ﬁrst such receptor involved in RBCs se-
questration. GAGs polysaccharides chains are usually com-
posed of repeats of disaccharides units formed by one hex-
uronicacidandonehexosamine.Atleastoneofthedisaccha-
ride elements has a carboxyl or a sulfate negatively charged.
Among major GAGs are hyaluronic acid (HA), chondroitin
sulfate,keratinsulfate,heparansulfate,andheparin.Heparin
is mostly a component of intracellular granules of mast cells
lining the arteries of the lungs, liver, and skin while heparan
sulfate is a component of the cell surface found in the base-
ment membrane. HS contains heparin-like motifs that are
enriched with N-sulfated glucosamine and 2-sulfated acidsN. T. Ndam and P. Deloron 3
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Figure 1: Schematic diagram of knobs showing potential intermolecular interactions between parasites proteins exported on the surface
of PRBC and receptors on the host cell surface. PfEMP, Plasmodium falciparum erythrocyte membrane protein; KHARP, knob-associated
histidine-rich protein; RIFIN, repetitive-interspersed family proteins; CLAG, cytoadherence-linked asexual protein; CR1, complement re-
ceptor 1; ICAM1, intercellular adhesion molecule 1; PECAM1, platelet endothelial cell adhesion molecule 1; CSA, chondroitin sulphate A;
UPP, uncharacterized parasite proteins. The question mark “?” means that the binding to hyaluronic acid is controversial.
[34]. Classical structure of CSA is tandem repeats of glu-
curonic acid [1–3]a n dN-acetylgalactosamine-4-sulfate [1–
4]. Figure 2 illustrates structures of the diﬀerent kinds of dis-
accharides composing GAGs of physiological signiﬁcance. It
ismoreandmoreobviousthatGAGsstructureismuchmore
heterogeneous than previously thought [36, 37].
Chondroitin sulfates (CS) are mosaics formed by C4S
(CSA) or C6S (CSC) types of disaccharides. The belong-
ing to a CS type depends on the most abundant disac-
charide. In chondroitin sulfate B (CSB), glucuronic acid is
changed to iduronic acid, and in CSC, the N-galactosamine
sulfate group is in position 6, while CSD and CSE are usually
hyaluronate mix. CSB and CSC are not implicated in PBRC
adherence [38].
Other GAGs of physiological signiﬁcance include Type
III TGF-β receptor, also called betaglycan, that contains both
heparan and chondroitin sulphate chains [39]. CD44 fam-
ily is composed of molecules that can exist in the proteo-
glycan and nonproteoglycan forms. CD44 is a cell surface
receptor for hyaluronan [40] and is synthesized by lympho-
cytes, epithelial cells, ﬁbroblasts, glial cells, Kupfer cells, and
mesangial cells of the kidney. Like syndecans it has a short
intracellular C-terminal and highly-conserved domain and
a large extracellular domain [41]. Extracellular domain con-
tains three disulﬁde-bonded loops, and it has a high homol-
ogy with the hyaluronan binding region of aggrecan, link
protein, neurocan, and versican [42].
The nervous tissue well-characterized proteoglycans in-
clude phosphacan, NG2 proteoglycan, agrin, receptor-type
protein tyrosine phosphatase, and the aggregating proteo-
glycans neurocan and brevican. NG2 proteoglycan is a
cell membrane-associated chondroitin sulphate proteogly-
can present in nervous tissue cells that have not yet spe-
cialized into oligodendrocytes [43], but it has been found
also in developing mesenchyme and human melanoma cells.
The primary structure of NG2 proteoglycan consists of 2325
amino acids that code a 252kd core protein [43].
In the vascular bed, thrombomodulin (TM) is a trans-
membrane glycoprotein containing high CSA levels [44].
CSA is involved in TM function, mainly by linking and
inactivating the circulating form of thrombin, a coagula-
tion factor [45]. TM is highly present in vascular endothelia4 Journal of Biomedicine and Biotechnology
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Figure 2: Structure of diﬀerent kinds of GAG disaccharides of physiological signiﬁcance.
(∼100.000 molecules per cell), but also at the syncytiotro-
phoblast surface [46, 47], to which PRBCs bind in placenta
[26]. The speciﬁcity of CSA binding of PRBCs is demon-
strated by its full inhibition by either a minimum motif of
7 disaccharide units of the 4S type [48] or by chondroitinase
ABC treatment. CSA is also present in pulmonary and cere-
bralvascularendothelium,suggestingapossibleroleinother
severe forms of malaria [49].
Optimal binding of PRBCs in the placenta is observed in
the presence of ∼30% 4S disaccharides and ∼70% nonsul-
fated disaccharides with a minimal motif of 6 disaccharide
units [50]. This has been conﬁrmed with a C4S/C6S bovine
copolymer,althoughtheminimalmotifincluded4C4Sunits
instead of 2 in the case of that from human origin [51].
Chondroitin sulfate proteoglycans (CSPG) isolated from hu-
manplacentaarelowsulfated,witharound8%ofchainswith
a sulfate in position 4 (C4S) and the most part being nonsul-
fated [37]. This apparent discrepancy is explained by the fact
that, in the CSPG structure, sulfated groups are concentrated
in domains formed with 6 to 14 disaccharides [52]. These
sulfate-rich domains include 20 to 28% of C4S, as opposed
to the other regions.
Other studies demonstrate that HA is also involved in
placenta sequestration of PRBCs, as most of P. falciparum
placental isolates exhibit aﬃnity for this GAG [53, 54]. How-
ever,notallagreewiththisﬁnding[55].Withasimilarstruc-
ture as CSA, N-acetylgalactosamin in HA is not sulfated.
Because HA is also present at the surface of syncytiotro-
phoblasts [56] and endothelial cells from microvessels [57],
further studies are required to determine if HA represents a
receptor in itself.
Despite the commonly admitted role of CSA in placen-
tal sequestration of P. falciparum infected RBCs, the over-
all process might be more complex involving multiple re-
ceptors such as (IgG, IgM, HA, CSA) rather than exclusive
interaction with CSA [58]. A P. falciparum line selected ac-
cording to the IgG-binding phenotype, was also shown to
bind strongly to placental syncytiotrophoblasts, with a sim-
ilar proﬁle as wild isolates [59]. This binding is not inhib-
ited by glycosaminoglycans or by chondroitinase ABC andN. T. Ndam and P. Deloron 5
hyaluronidase treatment, but is inhibited by IgG-binding
proteins, suggesting that PfEMP1-containing domains that
are able to bind CSA may also harbor IgG and IgM binding
sites, oﬀering another linking possibility between the PRBCs
surface and Fc receptors expressed in the placenta.
5. VAR GENES FAMILY AND ANTIGENIC VARIATION
In P. falciparum, variant antigens (PfEMP1) expressed at
PRBCs surface are encoded by a family of genes called var
composed of around 60 copies per haploid genome [60].
Members of this family are distributed among all chromo-
somes, most being localized in the subtelomeric regions and
few in the central region of the chromosomes. Subtelomeric
var genes are more vulnerable to the recombination phe-
nomenon that aﬀects their structure. Gene duplication phe-
nomena are also frequent. These phenomena, known since
the ’30s [61], allow biological evolution and diversity. Se-
lected genes are mutated after duplication or recombined
with other members of the family, while transcription of the
others is repressed following mutation. In the genome of the
3D7 P. falciparum strain, the high number of truncated var
genes (pseudogenes) indicates the high frequency of gene
deletion events occurring in the genome.
As for primary sequences, the number of domains may
vary between var genes, as their size (from 3.9 to 13kb).
PfEMP1 proteins encoded by these genes show diﬀerences
that originate major antigenic variations at the erythrocyte
surface. Each PfEMP1 is constituted by an arrangement of
distinct domains. The extracellular part is encoded by var
gene exon 1, and possesses a variable N-terminal segment
(NTS), several “Duﬀy-binding like” (DBL) domains (named
following the Duﬀy-binding protein, the ﬁrst such domain
described, that allows P. vivax adherence to the Duﬀy anti-
gen), and cysteine interdomain rich regions (CIDR) [62].
Each DBL domain is approximately 300 Aa long. Depend-
ing on their Aa sequence, DBLs as well as CIDRs have been
classiﬁedinto5types(αtoε).InselectedPfEMP1s,thereisa
small fragment after DBLβ originating a DBLβC2 structure.
At the end of exon 1, there is a sequence of variable length
(SVL) and a hydrophobic region with the characteristics of
a transmembrane domain (TM) [63]. The entire PfEMP1
molecule is anchored to the erythrocyte membrane by this
TM domain, followed by an acidic C-terminal intracellular
conserved segment (ATS), encoded by exon 2 (Figure 3).
S e v e r a ls t u d i e sh a v ea s s o c i a t e dPfEMP1s family to
malaria pathogenesis, and the study of the function of the
various PfEMP1 molecules represents a research topic of
high interest for the development of prevention strategies.
The understanding of the mechanisms controlling var gene
expression is of utmost importance for the control of their
biological role. Var gene expression involves a set of regula-
tion mechanisms implicating activation, switching, and si-
lencing of localization sites. Studies of pre-erythrocytic mat-
uration stages showed that var gene expression operates in a
mutually exclusive fashion. Although several transcripts are
detectable in a given parasite, a single one is massively tran-
scribed as a full-length (untruncated) mRNA and expressed
at the PRBCs surface while the others are kept inactivated
(silencing) or give rise to truncated mRNA [64, 65]. Each var
gene is a single transcriptional unit that can be activated in
situ. The expression of the various members varies accord-
ing to the development stages [66], but only the expression
during the erythrocytic stages seems to play a major role in
the parasite development in relation to the immune system
escape. Although the expression proﬁle may change in vitro
without immune pressure, the expression of the same var
gene during long periods of time has often been observed.
The phenomenon appears to be highly diﬀerent in vivo. Re-
cent studies show a total change in the expression proﬁle fol-
lowing passage of the parasite in the mosquito, suggesting a
much higher in vivo switching rate [67, 68]. Selected genes
withaphysicalcolocalizationshowatendencytobeactivated
and expressed during the same development stage [66, 69].
Considering diﬀerences in gene structure, chromoso-
mal organization, and sequences of untranslated regions,
subgroupings of the var gene family have been proposed
[60, 70, 71] .T h ea n a l y s i so fg e n eu p s t r e a ms e q u e n c e sa l -
lowed to deﬁne 3 major types of sequences (promoter-like):
upsA, upsB, and upsC [60]. Two sequences belonging to the
var1 and var2 subfamilies formed independent groups cor-
responding to upsD and upsE, respectively [71]. These se-
quences are associated to the localization and the orienta-
tion of each var gene. Subtelomeric genes orientated towards
the telomere express promoter sequences of the upsA type,
thoseorientatedaroundthecentromereexpresspromoterse-
quences of the upsB type, and those located in the central
part of the chromosome, upsC-type sequences. Diﬀerential
transcription of var genes from diﬀerent localizations inside
chromosomes is likely to be a consequence of the diﬀeren-
tial expression of promoter-repressing elements. A silencing
mechanism associated to the intron has also been suggested
[72, 73]. Small size mRNA from some var gene introns, co-
operating with 5 -UTR sequences, is able to inhibit expres-
sion of these genes. The expression of a conserved var gene
lacking intron (varCOMMON)i n3 D 7a n d6 0t o7 0 %o fw i l d
isolates strengthens this hypothesis [74]. The high level of
similarity in var genes intronic promoter motifs suggests this
phenomenon is able to regulate var genes expression. Nu-
merous queries are still remaining unanswered regarding the
overall process regulating var genes expression and associ-
ated mechanisms. Changes in the chromatin structure have
been associated with the switching phenomenon [75, 76]. A
recent report by Chookajorn et al. [77] shows that an epi-
genetic memory that includes histone modiﬁcations remi-
niscent of those associated with gene transcription memory
found in the homeotic genes of Drosophila melanogaster is
involvedinthecontrolofvar genetranscription.Speciﬁcepi-
genetic mark consisting in methylation of histone H3 and ly-
sineK9onchromatinseemstoplayamajorroleintranscrip-
tional memory that can provide advantages to the parasites
in pathogenesis and immune evasion.
In in vitro cultured P. falciparum strains, switch rate is
higher in some lines (as ITG) than in others (as FCR3) [22].
In in vivo conditions, several factors may play a role in a
given var gene type selection and expression. In children and6 Journal of Biomedicine and Biotechnology
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Figure 3: Schematic diagram illustrating var gene and PfEMP1 organization. Domains with known binding properties are speciﬁed. NTS,
N-terminal sequence; DBL, Duﬀy-binding like; CIDR, cystein-rich interdomain; SVL, sequence of variable length; TM, transmembrane;
ATs, acidic terminal sequence.
malaria naive individuals, parasites tend to express selected
VSA(mainlyPfEMP1)typesatthesurfaceofPRBCs(forre-
viewsee[78]).Inthepregnantwoman,theplacentaallowsto
select for parasite subpopulations expressing one (or several)
PfEMP1s able to bind receptors that are present on the syn-
cytiotrophoblast surface. Mechanisms for selecting the var
gene speciﬁcally expressed by parasites binding the placenta
is currently unknown. Motifs of nuclear receptor sequences
from hormones have been observed in the promoter regions
of some var genes, but their putative function remains un-
known [79], and the mechanism underlying var genes selec-
tionisunclear.Givenitsimportance,thereisanobviousneed
of investigation.
6. PARASITE LIGANDS INVOLVED IN PLACENTAL
SEQUESTRATION
Studies of in vitro selected parasite lines evidenced three
PfEMP1 molecules that could be involved in placenta se-
questration, through interaction with C4S receptors or with
nonimmune Ig [59, 80, 81]. Although the CSA binding site
has been localized inside the DBLγ domain of PfEMP1
molecules encoded by the FCR3varCSA [81]a n dvarCS2
[80] genes, the role of these DBLγ domains in placenta
binding is now questioned. Conversely to CS2var genes,
FCR3varCSA genes are much conserved in various isolates
and were named var1csa or varCOMMON. Transcription of
these genes is not restricted to placental isolates [74, 82, 83],
and analyses by Northern blot and real-time quantitative
RT-PCR failed to demonstrate any overexpression of the
var1csa or varCS2 transcripts in parasite lines selected for
CSA adhesion [84–86]. More recent works on laboratory-
adapted parasite lines [85, 86] suggested that another var
gene is involved in CSA adherence and placenta sequestra-
tion. This gene, termed var2csa,i sl o c a l i z e do nc h r o m o -
some 12. Another gene with similar, but truncated, sequence
is located on chromosome 13. The PfEMP1 protein en-
coded by var2csa is constituted of 6 DBL domains, among
which 3 remain unclassiﬁed. The sequence diﬀers phyloge-
netically from that of other members of the family, and the
DBLαandDBLγ arelacking[60].Var2csa isstructurallycon-
served between isolates and its overexpression by placen-
tal isolates is now conﬁrmed [32]. However, the inability to
ﬁndVAR2CSAPfEMP1inPRBCsmembranesbyproteomic
approach was unexpected [87]. Moreover, a recent study
based on a strategy of cross-linking PRBCs with a radio-
iodinated photoactivable C4S dodecasaccharide (represent-
ing the minimum requirement for eﬃcient PRBCs bind-
ing) rather identiﬁed an ∼ 22kd protein but no protein
has been identiﬁed within the PfEMP1 molecular weight
range as a ligand for C4S [88]. This observation suggests
that a low molecular weight PRBCs surface protein is in-
volved in C4S binding. Even though these surprising ﬁnd-
ings do not exclude the role of VAR2CSA in the binding
of PRBCs to C4S as possible technical insuﬃciencies in the
experimental procedures would explain the inability to de-
tect VAR2CSA, it likely appears that parasite binding to C4S
not only might involve multiple binding sites within the
VAR2CSA [89] but also might necessitate a multiprotein
complex possibly comprising VAR2CSA PfEMP1 and otherN. T. Ndam and P. Deloron 7
proteins for which identiﬁcation remains an important goal
to achieve.
7. IMMUNITY TO PAM
Initially thought that PAM was due to pregnancy-related im-
munomodulation and humoral alteration, studies have now
establishedthatPAMiscausedbyP.falciparumwhichexpress
unique variant surface antigens (VSAPAM) that allow the par-
asite sequestration in the placenta [90] by binding to CSPG
receptorsonsyncytiotrophoblast[30,91].Anumberofstud-
ies have indicated that parasite-encoded VSA in the surface
of PRBCs are important targets for acquired protective im-
munity that develops following exposure to P. falciparum
parasites [92–95]. In the case of pregnancy malaria, women
who have suﬀered from PAM develop VSAPAM-speciﬁc anti-
CSA adhesive antibodies which are associated with pro-
tection from malaria in subsequent pregnancies [96, 97].
The diﬀerence in susceptibility to PAM between primigravid
women and multigravid women is attributed to the lack by
primigravidae of antibodies against this particular VSAPAM.
These protective antibodies are thought to recognize reason-
ably conserved parasite antigens, because sera and parasites
from pregnant women from diﬀerent malaria areas cross-
react [98]. This has raised hope for development of a vac-
cine to prevent PAM that should incorporate the PRBCs sur-
face proteins expressed by placental parasites. Recent studies
have shown that PAM parasites speciﬁcally transcribe high
level of var2csa, one of the most conserved subfamily of var
genes encoding a member of the PfEMP1 family [32, 99].
Antibodies to this particular VSAPAM was recently shown to
speciﬁcally label the surface of in vitro adapted CSA-selected
parasite [100]. Naturally acquired human monoclonal IgG1
antibodies were recently shown to react exclusively with in-
tact CSA-adhering PRBCs expressing VSAPAM [101]. Plasma
samples from individuals from malaria endemic areas recog-
nize VAR2CSA recombinant proteins in a sex- and parity-
dependent manner [100, 102] and a kinetic study demon-
stratedthatVAR2CSA-speciﬁcantibodieswereacquireddur-
ingpregnancyasanantiparasiteresponse[102].Highplasma
levels of anti-VAR2CSA antibodies early in pregnancy are
associated with lower risk of LBW [100] and long lasting
placental infections [102]. More recently it was shown that
mouseantibodiesraisedagainstVAR2CSADBLdomainscan
inhibit adhesion of placental isolates to CSA as up to 60%
[103]. These observations demonstrate that the antibody-
mediated mechanism of protection against PAM can involve
both adhesion-blocking antibodies as well as cytophilic pro-
cess such as phagocytosis and complement activation. This
is consistent with the ﬁnding by Megnekou et al. [104] that
PAM IgG in Cameroonian women is predominantly com-
posed of IgG1 and IgG3 subclasses.
It was previously suggested that var gene expression is
hierarchically structured in ﬁeld isolates, as the expression
of certain var genes was found to be associated with severe
malaria in young children [105]. An explanation would be
that the progeny of parasites expressing var gene products
that mediate the most eﬀective sequestration outgrows the
progeny of parasites expressing a molecule mediating less ef-
fective binding [105–107]. A similar process was observed in
theexpressionofVAR2CSAmoleculesassomesequencemo-
tifs on DBL3X were more likely to occur distinctly in para-
sites isolated from primi- and multigravidae [108]. This se-
quence variation may have great consequence on the devel-
opmentofprotectiveantibodiesasPAMsevereconsequences
are observed more among primigravidae.
The contribution of cell-mediated immunity in protec-
tion against PAM remains unclear. The maternofetal inter-
face is a complex network where numerous cytokines are se-
creted. Immunomodulation during pregnancy was ﬁrst con-
sidered to result from a Th1/Th2 bias to facilitate the fetal
allograft development, and resulting in a decrease of Th1-
type cytokines (TFN-α and IFN-γ)[ 109] and an increase of
Th2-type cytokines (IL-4, IL-10, TGF-β)[ 110, 111]. Later, it
was thought to result from monocyte activation and relative
lymphocyte inhibition [112]. Placental cytokines modulate
the antigen-presenting cell function by inhibiting or increas-
ing the expression of various molecules on the monocyte
surface. The development of P. falciparum in the placenta
causes an immune imbalance with an increase of inﬂam-
matory cytokines, IFN-γ and TNF-α [113–115], explaining
that immunomodulation is more important in the placen-
tal blood than in the peripheral blood [116]. This inﬂamma-
tory response is responsible for functional damages in pla-
cental villi, and disturbances of the fetomaternal exchanges,
leading to low birth weight [113, 117]. IFN-γ secretion by
mononuclear cellsof the intervillous blood is associated with
protection against PAM [118], demonstrating the implica-
tion of the cell response. High level of anti-inﬂammatory
cytokines is observed in multigravidae compared to primi-
gravidae, suggesting that involvement of cell-mediated im-
munity in the mechanism of protection would necessitate
a ﬁne balance in timing and production of pro- and anti-
inﬂammatory cytokines [119, 120].
8. TREATMENT AND PREVENTION: PERSPECTIVES
FOR HUMAN APPLICATION
Initially the World Health Organization (WHO) recom-
mended that pregnant women living in malaria-endemic
areas receive chemoprophylaxis with a safe and eﬀective
antimalarial drug as part of routine antenatal care. Al-
though this policy was widely adopted across sub-Saharan
Africa, program implementation was often poor or nonex-
istent, especially in East Africa. Due to a number of diﬃ-
culties encountered including the diﬃcult deliverability of
this strategy (poor adherence with weekly drug dosing) and
rising rates of resistance to most chemoprophylaxis regi-
mens, including chloroquine [121], WHO had to change
its recommendations. In 2002, after studies conducted in
Malawi and Kenya demonstrated that two treatment doses
of sulfadoxine-pyrimethamine (SP) administered as inter-
mittent preventive treatment (IPTp) during routine ante-
natal care decreased maternal anemia and diminished the
frequency of low birthweight [122–124], WHO developed
a strategic framework for the control of malaria during8 Journal of Biomedicine and Biotechnology
pregnancy in Africa [23]. The document recommends that
pregnant women receive at least two doses of IPTp during
the second and third trimesters at routine antenatal care vis-
its.Thepreventionstrategiesofmalariaduringpregnancyin-
clude IPTp, insecticide-treated nets, and eﬀective case man-
agement of clinical malaria. The new policy leading to the
adoption of IPTp is unique to pregnancy and is still un-
der evaluation. In contrast, insecticide-treated nets and case
management are strategies that are in use for all age and gen-
der strata.
A recent study using depolymerized heparin demon-
strated that these modiﬁed glycosaminoglycans (dGAGs) are
able to disrupt binding properties of P. falciparum that form
rosettes and employ heparan sulfate as a host receptor. Intra-
venous injection of these dGAGs could block up to 80% of
PRBCs from binding in the microvasculature and release al-
ready sequestered parasites into the circulation in an in vivo
model of severe malaria [125].
GAGs are structures contributing to host cell recognition
and invasion by various infectious agents, including viruses
(herpes simplex, viral hepatitis, HIV) and parasites (Babesia,
Leishmania, Plasmodium)( f o rr e vi e ws e e[ 126]). Three types
of GAGs interact with P. falciparum endo-erythrocytic cycle:
heparane sulfates [127] involved in rosette formation, CSA
in PRBCs adherence, and heparine in RBCs invasion inhi-
bition. As regards PRBCs adherence, it was shown that sol-
uble CSA is involved both in vivo and in vitro. Intravenous
injections of soluble CSA to monkeys infected with a CSA-
binding Plasmodium strain are followed by the release of
mature stages of the parasite in the peripheral blood [128].
Moreover, PBRCs in vitro binding is inhibited by almost
90% by puriﬁed CSA. These observations originated works
related to the inhibitory capacity of CS. Hitherto, various
polysaccharides have been tested for their ability to inhibit
humanerythrocyteinvasionbyP.falciparummerozoites,and
PBRCs binding to various receptors [129–132]. Numerous
sulfated polysaccharides, such as heparines, sulfate dextrans,
fucoidans, and hyaluronates all exhibit inhibitory properties,
but at diﬀerent levels. Two carraghenate derivatives and cel-
lulose sulfate (CS10) inhibit PRBCs binding to CSA [133].
Chondroitin-4-sulfate, a molecule already marketed (Chon-
drosulf, Structum), was unable to inhibit PRBCs binding to
Saimiri endothelium [128], but this was probably related to
the oral administration of the drug. Intravenous administra-
tion of Structum was eﬀective in Saimiri, but the drug of
bovine origin is not anymore available. Industrial synthe-
sis of glycosaminoglycans cannot be currently achieved. It
is necessary to conduct additional structural and toxicologic
studies of CS, for this to be considered as a potential candi-
date for treating PAM.
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